Cumulative lifetime penetrance estimates for female breast cancer are taken from the literature review performed by the All Syndromes Known to Man Evaluator28–32: 0.35 (ATM), 0.73 (BRCA1), 0.72 (BRCA2), 0.19 (CHEK2), and 0.38 (PALB2). This evidence concerns the gene PALB2 and breast carcinoma.